Windtree Therapeutics, a Nasdaq-listed biotech firm, plans to purchase up to $700 million worth of BNB, following the cryptocurrency's recent all-time high. The company aims to bolster its balance sheet with BNB, acquiring up to $520 million in funding through a $500 million equity line of credit and a $20 million stock purchase agreement. This purchase strategy mirrors that of other publicly traded companies, like Strategy, which have begun acquiring digital assets to enhance stock prices. Windtree has partnered with crypto exchange Kraken for custody and trading of its BNB holdings. Currently, BNB ranks as the fifth largest cryptocurrency, recently trading at around $769, with a peak of $808 this week. Despite a 5% dip in shares this Friday, the stock has surged 162% over the past month, reflecting investor confidence amid a trend of companies diversifying their portfolios with cryptocurrencies.

Source đź”—